Quest Diagnostics director reports small share acquisition

Quest Diagnostics Inc. director Wright Lassiter III reported a small acquisition of common stock.

Accepted by SEC EDGAR 07/27/2026 - 04:33 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Quest Diagnostics Inc. director Wright Lassiter III reported a small acquisition of common stock. On 2026-07-22, he acquired 6 shares at $206.813 per share through a dividend reinvestment plan administered by his broker, increasing his direct holdings to 10,323 shares. The transaction was eligible for deferred reporting on Form 5 under Rule 16a-6, but he chose to report it early on Form 4. The Rule 10b5-1 checkbox was not marked as a trading plan.

Insider Trade Summary

Small Acquisition: 6 shares

Small Acquisition 1 txn

Insider Lassiter Wright III

Role Director

Type	Security	Shares	Price	Value
Small Acquisition	Common Stock F1	6	$206.813	$1K

Holdings After Transaction: Common Stock — 10,323 shares (Direct)

Footnotes (1)

1. F1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

Key Figures

Shares acquired: 6 shares of Common Stock Price per share: $206.8130 per share Post-transaction holdings: 10,323 shares

3 metrics

Shares acquired 6 shares of Common Stock Shares acquired on 2026-07-22 via dividend reinvestment plan

Price per share $206.8130 per share Acquisition price for 6 Quest Diagnostics shares

Post-transaction holdings 10,323 shares Direct ownership after the reported acquisition

Key Terms

dividend reinvestment plan, Rule 16a-6, Form 5

3 terms

dividend reinvestment plan financial

"Reflects shares that were acquired pursuant to a dividend reinvestment plan administered"

A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.

Rule 16a-6 regulatory

"eligible for deferred reporting on Form 5 under Rule 16a-6"

Form 5 regulatory

"eligible for deferred reporting on Form 5 under Rule 16a-6"

A Form 5 is an annual report filed with the U.S. securities regulator by company insiders—such as officers, directors and large shareholders—to disclose any equity transactions or holdings that were missed or deferred during the year. Think of it as an end-of-year ledger adjustment that shows final insider ownership and late-reported trades; investors use it to verify insider confidence, detect possible conflicts of interest, and spot unusual patterns in insiders’ buying or selling.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Wright Lassiter III report for DGX on this Form 4?

Wright Lassiter III reported a small acquisition of 6 shares of Quest Diagnostics common stock. The acquisition occurred on 2026-07-22 through a dividend reinvestment plan, and it increased his direct holdings to 10,323 shares following the transaction.

At what price were the Quest Diagnostics (DGX) shares acquired by Wright Lassiter III?

The reported acquisition was priced at $206.813 per share for Quest Diagnostics common stock. The 6 shares were obtained via a broker-administered dividend reinvestment plan, as described in the footnote to the Form 4 filing.

How many Quest Diagnostics (DGX) shares does Wright Lassiter III own after this transaction?

After the reported transaction, Wright Lassiter III directly owns 10,323 shares of Quest Diagnostics common stock. This reflects the addition of 6 shares acquired on 2026-07-22 through a dividend reinvestment plan eligible for deferred reporting under Rule 16a-6.

How were the DGX shares acquired in Wright Lassiter III’s Form 4 filing?

The shares were acquired through a dividend reinvestment plan administered by Wright Lassiter III’s broker. The footnote explains the plan purchases 6 shares of Quest Diagnostics common stock, which were then reported early on Form 4 despite eligibility for Form 5 reporting.

Why is Rule 16a-6 mentioned in the Quest Diagnostics (DGX) Form 4 filing?

Rule 16a-6 is cited because the dividend reinvestment plan acquisition was eligible for deferred reporting on Form 5. The reporting person voluntarily chose to disclose this small transaction early on Form 4 instead of waiting to include it on a later Form 5.

Was Wright Lassiter III’s DGX transaction made under a Rule 10b5-1 trading plan?

The filing does not characterize the transaction as under a Rule 10b5-1 plan. Instead, the footnote attributes the acquisition to a broker-administered dividend reinvestment plan, and the transaction is described as eligible for deferred reporting under Rule 16a-6.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lassiter Wright III

(Last) (First) (Middle)

500 PLAZA DRIVE

C/O QUEST DIAGNOSTICS

(Street)

SECAUCUS NEW JERSEY 07094

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/22/2026		L	V	6(1)	A	$206.813	10,323	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

Remarks:

	Sean D. Mersten, Attorney in Fact for Wright L. Lassiter, III	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)